Skip to main content
. 2023 Oct 4;14:1270796. doi: 10.3389/fendo.2023.1270796

Table 2.

Outcome of DTC in different ATA and TNM stages showing more persistent thyroid cancer in higher stages.

ATA risk group NED
No. (%)
PD
No. (%)
P value
Low risk 77 (80.2) 19 (19.8) <0.0001
Intermediate risk 77 (64) 48 (38.4)
High risk 21 (28.0) 54 (72.0)
TNM stages
I 68 (68.7) 31 (31.3) <0.001
II 97 (64.7) 53 (35.3)
III 9 (33.3) 18 (66.7)
IV 1 (5) 19 (95)
Total 175 (59) 121 (41)

NED, no evidence of disease; PD, persistent disease.